Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 20, 2025
Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic
GlobeNewswire
·
May 20, 2025
The program, licensed exclusively to BMS, represents the third ADC candidate using the company’s proprietary Tubutecan technology to reach the clinic. MUNICH, GERMANY, May 20, 2025 – Tubulis today announced that the first program from its strategic …
Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists
GlobeNewswire
·
May 20, 2025
Two-part preclincal and clinical development programme launched to assess potential benefits of administering S-pindolol benzoate during and post-GLP-1 receptor agonist therapy to improve muscle mass, cardiac protection and bone mineral density in obese …
EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer
GlobeNewswire
·
May 20, 2025
These results indicate that EXACT Therapeutics’ Acoustic Cluster Therapy (ACT®) significantly enhances the local effect of chemotherapy In the patients who had a response to chemotherapy, ACT-treated tumours showed a significantly greater reduction in …
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
GlobeNewswire
·
May 20, 2025
Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its antibiotic …
Basilea gibt Verkaufsstart seines Antibiotikums Zevtera® (Ceftobiprol) in den USA bekannt
GlobeNewswire
·
May 20, 2025
Allschwil, 20. Mai 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab …
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
GlobeNewswire
·
May 20, 2025
VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today the appointment of Rick Austin, Ph.D. as Chief Scientific …
Award-Winning Disposable Weed Pen & THC Carts | Back in Stock at Area 52
GlobeNewswire
·
May 20, 2025
Las Vegas, NV, May 19, 2025 (GLOBE NEWSWIRE) -- Following an unprecedented two-month sell-out due to overwhelming popularity, Area 52, the biochemist-led brand celebrated for its mastery in cannabinoid science and honored as #1 by High Times Magazine, …
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
GlobeNewswire
·
May 20, 2025
BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a …